Qilu Pharmaceutical Launches Phase I Clinical Trial of QLH2405, Its First Class 1 New Drug for Alzheimer's Disease

(Source: Qiu Shi Pharmacy)

On March 17, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Qilu Pharmaceutical Co., Ltd. registeredOne itemA Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Subcutaneous, Dose-escalation Injections of QLH2405 in Healthy Participants and Those with Mild Cognitive Impairment and Mild Alzheimer's Disease of Alzheimer's Origin.

Official Website of Drug Clinical Trial Registration and Information Disclosure Platform

The study plans to enroll 68 subjects, who will be randomly assigned to receiveQLH2405 and placebo treatment, administered via abdominal subcutaneous injection with dose escalation.The primary endpoint was the incidence and severity of adverse events., secondary endpoints includeTmax, Cmax, AUC0-t, etc.

Insight database shows that Qilu Pharmaceutical Co., Ltd. is currently developingThree new drugs for Alzheimer's disease, including the improved new drug Memantine Oral Soluble Film, have been launched in China.QLH2405 is the first to enter the clinical stageNew Drug for Alzheimer's DiseaseClass 1 New Drug.

DXY Insight Database

The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints presented, and does not provide any express or implied guarantees regarding the accuracy, reliability, or completeness of the content included. Readers are advised to use it solely as a reference and assume full responsibility on their own.